TO CMPAIRE THE DISSOLUTION PROFILE OF VARIOUS BRANDS OF PARACETAMOL
•
1 like•105 views
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms for those who already suffer from conditions like anxiety and depression.
Report
Share
Report
Share
Download to read offline
Recommended
ICSR (individual case safety report)
The document discusses individual case safety reports (ICSRs) and the process for reporting adverse drug reactions (ADRs). An ICSR contains identifiable information about the reporter, patient, suspected adverse event, and suspected medicinal product. The steps for reporting include ICSR collection, processing, data entry, quality review, and medical review. Key requirements are that an ICSR contains identifiable information on the reporter, patient, suspected ADR, and suspected product to allow for reporting of ADRs occurring in single patients.
Spontaneous reporting
Spontaneous reporting involves unsolicited communication about suspected adverse drug reactions (ADRs) to regulatory authorities from healthcare professionals or consumers. Passive surveillance relies on voluntary ADR reporting by health professionals, while active surveillance uses organized monitoring systems. The Pharmacovigilance Programme of India (PvPI) currently uses spontaneous reporting to collect drug safety data. Reporting forms collect patient information, reaction details, suspected medications, and reporter information to submit individual case safety reports (ICSRs) on suspected ADRs. Both healthcare professionals and consumers can report ADRs to the National Coordination Centre (NCC) to help ensure public health and drug safety.
Regulatory requirements for drug approval
B. Pharm. Final Year, Sem:- VII, INDUSTRIAL PHARMACY-II,
Unit 3 chapter 4 Regulatory requirements for drug approval,
As per PCI Syllabus
INVESTIGATIONAL NEW DRUG APPLICATION
An Investigational New Drug (IND) application allows a sponsor to lawfully use an investigational drug for clinical investigation purposes. It provides information on preclinical testing, clinical protocols, manufacturing, and investigator qualifications to ensure subject safety. An IND is required for clinical studies intended to support a new indication, change in dosage/administration, or different patient population. It exempts the sponsor from prohibitions on shipping unapproved drugs and facilitates three phases of clinical trials to evaluate safety and efficacy.
INVESTIGATIONAL NEW DRUG (IND)
This document provides an overview of the Investigational New Drug (IND) application process. It discusses how an IND is required to begin clinical trials on new drugs and allows pharmaceuticals to be transported between states for research purposes. The document outlines the various stages of pre-clinical and clinical testing, including pre-clinical studies in animals to establish safety, and the three phases of human clinical trials. It provides details on the key components of an IND application, including chemistry and manufacturing information, clinical protocols, and safety data from non-clinical studies. The overall goal of an IND is to obtain permission from the FDA to begin human clinical trials by demonstrating the new drug and trial design will not place subjects at unreasonable risk.
Pharmacovigilance systems & methodologies across the globe
The document discusses various pharmacovigilance systems and methodologies used around the world to monitor the safety of medicines. It describes the WHO global database VigiBase which contains reports of adverse drug reactions. It also outlines other pharmacovigilance systems like EudraVigilance in Europe, FAERS in the US, Canada Vigilance in Canada, and the Yellow Card Scheme in the UK. The document then discusses data mining and analysis techniques used for pharmacovigilance, including those for pre-marketing surveillance using computational approaches as well as those for post-marketing surveillance using spontaneous reporting systems, electronic health records, and non-traditional data sources.
WHO International Drug Monitoring Program
The WHO International Drug Monitoring Program was established in 1963 in response to the thalidomide disaster. It currently has 143 member countries that submit adverse drug reaction reports to the global pharmacovigilance database VigiBase managed by the Uppsala Monitoring Centre (UMC) as a WHO collaborating center. The UMC analyzes VigiBase data to identify new safety signals, conducts research, and provides tools and training to support member countries' pharmacovigilance activities. The overall goals are to identify unknown adverse drug reactions and ensure medicines are used safely worldwide.
Drug safety evaluation in clinical trial
This document discusses drug safety evaluation in clinical trials. It provides an overview of safety concerns, sources of safety information, safety monitoring and reporting requirements. Safety is evaluated using data from nonclinical studies, clinical trials and postmarketing reports. Adverse events are monitored and assessed for causality. Serious adverse events must be reported expediently to regulatory agencies. Ongoing evaluation is needed to identify unexpected or rare safety issues.
Recommended
ICSR (individual case safety report)
The document discusses individual case safety reports (ICSRs) and the process for reporting adverse drug reactions (ADRs). An ICSR contains identifiable information about the reporter, patient, suspected adverse event, and suspected medicinal product. The steps for reporting include ICSR collection, processing, data entry, quality review, and medical review. Key requirements are that an ICSR contains identifiable information on the reporter, patient, suspected ADR, and suspected product to allow for reporting of ADRs occurring in single patients.
Spontaneous reporting
Spontaneous reporting involves unsolicited communication about suspected adverse drug reactions (ADRs) to regulatory authorities from healthcare professionals or consumers. Passive surveillance relies on voluntary ADR reporting by health professionals, while active surveillance uses organized monitoring systems. The Pharmacovigilance Programme of India (PvPI) currently uses spontaneous reporting to collect drug safety data. Reporting forms collect patient information, reaction details, suspected medications, and reporter information to submit individual case safety reports (ICSRs) on suspected ADRs. Both healthcare professionals and consumers can report ADRs to the National Coordination Centre (NCC) to help ensure public health and drug safety.
Regulatory requirements for drug approval
B. Pharm. Final Year, Sem:- VII, INDUSTRIAL PHARMACY-II,
Unit 3 chapter 4 Regulatory requirements for drug approval,
As per PCI Syllabus
INVESTIGATIONAL NEW DRUG APPLICATION
An Investigational New Drug (IND) application allows a sponsor to lawfully use an investigational drug for clinical investigation purposes. It provides information on preclinical testing, clinical protocols, manufacturing, and investigator qualifications to ensure subject safety. An IND is required for clinical studies intended to support a new indication, change in dosage/administration, or different patient population. It exempts the sponsor from prohibitions on shipping unapproved drugs and facilitates three phases of clinical trials to evaluate safety and efficacy.
INVESTIGATIONAL NEW DRUG (IND)
This document provides an overview of the Investigational New Drug (IND) application process. It discusses how an IND is required to begin clinical trials on new drugs and allows pharmaceuticals to be transported between states for research purposes. The document outlines the various stages of pre-clinical and clinical testing, including pre-clinical studies in animals to establish safety, and the three phases of human clinical trials. It provides details on the key components of an IND application, including chemistry and manufacturing information, clinical protocols, and safety data from non-clinical studies. The overall goal of an IND is to obtain permission from the FDA to begin human clinical trials by demonstrating the new drug and trial design will not place subjects at unreasonable risk.
Pharmacovigilance systems & methodologies across the globe
The document discusses various pharmacovigilance systems and methodologies used around the world to monitor the safety of medicines. It describes the WHO global database VigiBase which contains reports of adverse drug reactions. It also outlines other pharmacovigilance systems like EudraVigilance in Europe, FAERS in the US, Canada Vigilance in Canada, and the Yellow Card Scheme in the UK. The document then discusses data mining and analysis techniques used for pharmacovigilance, including those for pre-marketing surveillance using computational approaches as well as those for post-marketing surveillance using spontaneous reporting systems, electronic health records, and non-traditional data sources.
WHO International Drug Monitoring Program
The WHO International Drug Monitoring Program was established in 1963 in response to the thalidomide disaster. It currently has 143 member countries that submit adverse drug reaction reports to the global pharmacovigilance database VigiBase managed by the Uppsala Monitoring Centre (UMC) as a WHO collaborating center. The UMC analyzes VigiBase data to identify new safety signals, conducts research, and provides tools and training to support member countries' pharmacovigilance activities. The overall goals are to identify unknown adverse drug reactions and ensure medicines are used safely worldwide.
Drug safety evaluation in clinical trial
This document discusses drug safety evaluation in clinical trials. It provides an overview of safety concerns, sources of safety information, safety monitoring and reporting requirements. Safety is evaluated using data from nonclinical studies, clinical trials and postmarketing reports. Adverse events are monitored and assessed for causality. Serious adverse events must be reported expediently to regulatory agencies. Ongoing evaluation is needed to identify unexpected or rare safety issues.
Schedule Y
Requirements And Guidelines For Permission To Import / or Manufacture of New Drugs For Sale or To Undertake Clinical Trials
Schedule Y was introduced under the Drugs and Cosmetics Act 1940, to
introduce requirements for countries to get permission for:
Importing
Manufacturing new drugs
Conducting Clinical Trials.
Application for permission
Clinical Trial
Studies in specific population
Post marketing surveillance
Special studies: BA/BE studies
Role of drug regulatory agencies
Drug regulatory agencies play a critical role in ensuring the safety, efficacy, and quality of pharmaceutical products, including drugs, biologics, and medical devices. These agencies are responsible for establishing and enforcing regulations and guidelines that govern the development, testing, approval, manufacturing, labeling, marketing, and post-market surveillance of these products.
Schedule y
This document outlines the rules and regulations for conducting clinical trials and importing or manufacturing new drugs in India. It discusses the various forms and permissions required, including Form 44 for new drug approval and Form 12 for importing study drugs. It also describes the responsibilities of sponsors, investigators, and ethics committees. The document explains the different phases of clinical trials from human pharmacology to post-marketing surveillance. It lists the data that must be submitted with applications and included in clinical study reports.
Pharmacovigilance program of India (PvPI)
This document provides an overview of pharmacovigilance in India, including:
- The history of pharmacovigilance efforts in India from 1986 to the present.
- The objectives and goals of the current Pharmacovigilance Program of India (PvPI), including establishing a nationwide safety reporting system and expanding electronic reporting.
- The roles and responsibilities of stakeholders like the National Coordinating Center, Advisory Monitoring Centers, and CDSCO in the PvPI.
Causality Assessment ADR.pdf
This document discusses different methods for assessing the causality of adverse drug reactions (ADRs). It describes three main types of methods: 1) Expert opinion or clinical judgment methods like the WHO causality assessment scale, 2) Algorithmic methods like the Naranjo scale that use questionnaires and scoring systems, 3) Probabilistic or Bayesian methods that calculate the probability of drug causation based on prior probabilities. The WHO scale and Naranjo scale are discussed in detail as examples of each method.
Pharmacovigilance overview shraddha
Pharmacovigilance-definition and importance
adverse drug reaction and adverse events
type of reporters
valid or invalid ADR
listedness/expectedness
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
International Nonproprietary Names (INNs) provide a unique name for each pharmaceutical substance to aid clear identification and safe use worldwide. The WHO manages the INN system, selecting names through a process involving proposed names, an objection period, and final recommended INNs. INNs aim to identify substances uniquely while avoiding names that could cause confusion or be proprietary. Principles for selection include being distinctive, concise, and avoiding confusion with other names. Stem elements are often used to group related substances.
Med-DRA
MedDRA is a terminology used in pharmacovigilance which is used in coding the different aspects in clinical study reports.
Pharmacovigilance regulations as per European Union
pharmacovigilance, ADR, Side effects, Processing plan, Eudravigilance, Partners, Benefits of Monitoring
Pharmacovigilance
Pharmacovigilance is science of detection,
assessment, reporting and prevention of adverse
reactions to drug(s).
Major aims of pharmacovigilance are:
1. Early detection of hitherto unknown adverse
reactions and interactions
2. Detection of increases in frequency of (known)
adverse reactions
3. Identification of risk factors and possible
mechanisms underlying adverse reactions
4. Estimation of quantitative aspects of benefit/risk
analysis and dissemination of information needed to
improve drug prescribing and regulation.
Information on Pharmacovigilance.pptx
This document provides information on establishing pharmacovigilance programs and resources in pharmacovigilance. It discusses the importance of classification systems like ATC, ICD, and INN for monitoring drugs and adverse events. Primary resources include clinical trial data and reports, while secondary resources summarize primary sources. Tertiary sources compile information from multiple sources. Establishing an effective pharmacovigilance program requires a structured organization, trained staff, coordination between stakeholders, and support from regulatory authorities and healthcare priorities. Monitoring drug safety is crucial for public health.
DRUG SAFETY REPORTING.pptx
Drug safety reporting has a vital role in the pre-approval and post-approval phases. It is essential for the safety of the public.
History of Pharmacovigilance
Concept of Pharmacovigilance, history and development of pharmacovigilance, WHO International drug monitoring programme, Pharmacovigilance programme of India
Regulatory affairs - industrial pharmacy II
click here
jsmasipharmacy.blogspot.com
https://jsmasipharmacy.blogspot.com/2020/10/regulatory-affairs-industrial-pharmacy.html
ICH: Introduction, objectives & guidelines: A brief insight.
This is my 44th powerpoint........deals with ICH guidelines.....
Deals with brief introduction, precise objectives, organization(in short) & guidelines (in precise), based on SAFETY, EFFICACY, QUALITY & MULTIDISCIPLINARY guidelines.
Happy reading!!
:)
Methods in causality assessment.pptx
Chetan G. Kumbhar's topic discusses methods for assessing causality between drug treatments and adverse reactions or events. There are three main categories of causality assessment methods: 1) expert judgment, which relies on an expert's experience and knowledge; 2) algorithms, which use standardized tools like the Naranjo scale to calculate the likelihood of causation; and 3) probabilistic methods, which use Bayesian statistics to transform prior probabilities into posterior probabilities of drug causation based on epidemiological data and evidence from a particular case. The goal of causality assessment is to determine relationships between drugs and adverse events, detect new safety signals, better understand drug toxicities and benefits, and evaluate adverse drug reaction reports.
ANDA
The document provides information about abbreviated new drug applications (ANDAs), which are designed to allow approval of generic drug products that are equivalent to already approved brand name drugs. An ANDA must show a generic drug is comparable to the reference drug in dosage form, strength, quality and performance. It does not require preclinical and clinical trials but must demonstrate bioequivalence through bioavailability and bioequivalence studies. The ANDA contents and review process are outlined according to the Common Technical Document format in five quality, nonclinical, and clinical modules.
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
B. Pharm. Final Year, Sem-VIII, BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory),
As PCI Syllabus.
manufacturing of parenterals
This document discusses the manufacture of small volume and large volume parenterals. Small volume parenterals have volumes less than or equal to 100ml and are supplied in single or multiple doses, while large volume parenterals have volumes greater than 100ml and are delivered via intravenous route. The key aspects of formulation include therapeutic agents, vehicles like water for injection, and added substances like antimicrobials, antioxidants and buffers. Terminal sterilization is used to assure sterility of the finished products.
Generics And Innovators
An innovator or branded drug is the first drugs created containing its specific active ingredient to receive approval for use.
A generic drug is made of the same active ingredient as its innovator drug.
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty,
International FDP on Fundamentals of Research in Social Sciences
at Integral University, Lucknow, 06.06.2024
By Dr. Vinod Kumar KanvariaThe Diamonds of 2023-2024 in the IGRA collection
A review of the growth of the Israel Genealogy Research Association Database Collection for the last 12 months. Our collection is now passed the 3 million mark and still growing. See which archives have contributed the most. See the different types of records we have, and which years have had records added. You can also see what we have for the future.
More Related Content
What's hot
Schedule Y
Requirements And Guidelines For Permission To Import / or Manufacture of New Drugs For Sale or To Undertake Clinical Trials
Schedule Y was introduced under the Drugs and Cosmetics Act 1940, to
introduce requirements for countries to get permission for:
Importing
Manufacturing new drugs
Conducting Clinical Trials.
Application for permission
Clinical Trial
Studies in specific population
Post marketing surveillance
Special studies: BA/BE studies
Role of drug regulatory agencies
Drug regulatory agencies play a critical role in ensuring the safety, efficacy, and quality of pharmaceutical products, including drugs, biologics, and medical devices. These agencies are responsible for establishing and enforcing regulations and guidelines that govern the development, testing, approval, manufacturing, labeling, marketing, and post-market surveillance of these products.
Schedule y
This document outlines the rules and regulations for conducting clinical trials and importing or manufacturing new drugs in India. It discusses the various forms and permissions required, including Form 44 for new drug approval and Form 12 for importing study drugs. It also describes the responsibilities of sponsors, investigators, and ethics committees. The document explains the different phases of clinical trials from human pharmacology to post-marketing surveillance. It lists the data that must be submitted with applications and included in clinical study reports.
Pharmacovigilance program of India (PvPI)
This document provides an overview of pharmacovigilance in India, including:
- The history of pharmacovigilance efforts in India from 1986 to the present.
- The objectives and goals of the current Pharmacovigilance Program of India (PvPI), including establishing a nationwide safety reporting system and expanding electronic reporting.
- The roles and responsibilities of stakeholders like the National Coordinating Center, Advisory Monitoring Centers, and CDSCO in the PvPI.
Causality Assessment ADR.pdf
This document discusses different methods for assessing the causality of adverse drug reactions (ADRs). It describes three main types of methods: 1) Expert opinion or clinical judgment methods like the WHO causality assessment scale, 2) Algorithmic methods like the Naranjo scale that use questionnaires and scoring systems, 3) Probabilistic or Bayesian methods that calculate the probability of drug causation based on prior probabilities. The WHO scale and Naranjo scale are discussed in detail as examples of each method.
Pharmacovigilance overview shraddha
Pharmacovigilance-definition and importance
adverse drug reaction and adverse events
type of reporters
valid or invalid ADR
listedness/expectedness
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
International Nonproprietary Names (INNs) provide a unique name for each pharmaceutical substance to aid clear identification and safe use worldwide. The WHO manages the INN system, selecting names through a process involving proposed names, an objection period, and final recommended INNs. INNs aim to identify substances uniquely while avoiding names that could cause confusion or be proprietary. Principles for selection include being distinctive, concise, and avoiding confusion with other names. Stem elements are often used to group related substances.
Med-DRA
MedDRA is a terminology used in pharmacovigilance which is used in coding the different aspects in clinical study reports.
Pharmacovigilance regulations as per European Union
pharmacovigilance, ADR, Side effects, Processing plan, Eudravigilance, Partners, Benefits of Monitoring
Pharmacovigilance
Pharmacovigilance is science of detection,
assessment, reporting and prevention of adverse
reactions to drug(s).
Major aims of pharmacovigilance are:
1. Early detection of hitherto unknown adverse
reactions and interactions
2. Detection of increases in frequency of (known)
adverse reactions
3. Identification of risk factors and possible
mechanisms underlying adverse reactions
4. Estimation of quantitative aspects of benefit/risk
analysis and dissemination of information needed to
improve drug prescribing and regulation.
Information on Pharmacovigilance.pptx
This document provides information on establishing pharmacovigilance programs and resources in pharmacovigilance. It discusses the importance of classification systems like ATC, ICD, and INN for monitoring drugs and adverse events. Primary resources include clinical trial data and reports, while secondary resources summarize primary sources. Tertiary sources compile information from multiple sources. Establishing an effective pharmacovigilance program requires a structured organization, trained staff, coordination between stakeholders, and support from regulatory authorities and healthcare priorities. Monitoring drug safety is crucial for public health.
DRUG SAFETY REPORTING.pptx
Drug safety reporting has a vital role in the pre-approval and post-approval phases. It is essential for the safety of the public.
History of Pharmacovigilance
Concept of Pharmacovigilance, history and development of pharmacovigilance, WHO International drug monitoring programme, Pharmacovigilance programme of India
Regulatory affairs - industrial pharmacy II
click here
jsmasipharmacy.blogspot.com
https://jsmasipharmacy.blogspot.com/2020/10/regulatory-affairs-industrial-pharmacy.html
ICH: Introduction, objectives & guidelines: A brief insight.
This is my 44th powerpoint........deals with ICH guidelines.....
Deals with brief introduction, precise objectives, organization(in short) & guidelines (in precise), based on SAFETY, EFFICACY, QUALITY & MULTIDISCIPLINARY guidelines.
Happy reading!!
:)
Methods in causality assessment.pptx
Chetan G. Kumbhar's topic discusses methods for assessing causality between drug treatments and adverse reactions or events. There are three main categories of causality assessment methods: 1) expert judgment, which relies on an expert's experience and knowledge; 2) algorithms, which use standardized tools like the Naranjo scale to calculate the likelihood of causation; and 3) probabilistic methods, which use Bayesian statistics to transform prior probabilities into posterior probabilities of drug causation based on epidemiological data and evidence from a particular case. The goal of causality assessment is to determine relationships between drugs and adverse events, detect new safety signals, better understand drug toxicities and benefits, and evaluate adverse drug reaction reports.
ANDA
The document provides information about abbreviated new drug applications (ANDAs), which are designed to allow approval of generic drug products that are equivalent to already approved brand name drugs. An ANDA must show a generic drug is comparable to the reference drug in dosage form, strength, quality and performance. It does not require preclinical and clinical trials but must demonstrate bioequivalence through bioavailability and bioequivalence studies. The ANDA contents and review process are outlined according to the Common Technical Document format in five quality, nonclinical, and clinical modules.
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
B. Pharm. Final Year, Sem-VIII, BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory),
As PCI Syllabus.
manufacturing of parenterals
This document discusses the manufacture of small volume and large volume parenterals. Small volume parenterals have volumes less than or equal to 100ml and are supplied in single or multiple doses, while large volume parenterals have volumes greater than 100ml and are delivered via intravenous route. The key aspects of formulation include therapeutic agents, vehicles like water for injection, and added substances like antimicrobials, antioxidants and buffers. Terminal sterilization is used to assure sterility of the finished products.
Generics And Innovators
An innovator or branded drug is the first drugs created containing its specific active ingredient to receive approval for use.
A generic drug is made of the same active ingredient as its innovator drug.
What's hot (20)
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
Pharmacovigilance regulations as per European Union
Pharmacovigilance regulations as per European Union
ICH: Introduction, objectives & guidelines: A brief insight.
ICH: Introduction, objectives & guidelines: A brief insight.
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
Recently uploaded
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty,
International FDP on Fundamentals of Research in Social Sciences
at Integral University, Lucknow, 06.06.2024
By Dr. Vinod Kumar KanvariaThe Diamonds of 2023-2024 in the IGRA collection
A review of the growth of the Israel Genealogy Research Association Database Collection for the last 12 months. Our collection is now passed the 3 million mark and still growing. See which archives have contributed the most. See the different types of records we have, and which years have had records added. You can also see what we have for the future.
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
বাংলাদেশের অর্থনৈতিক সমীক্ষা ২০২৪ [Bangladesh Economic Review 2024 Bangla.pdf] কম্পিউটার , ট্যাব ও স্মার্ট ফোন ভার্সন সহ সম্পূর্ণ বাংলা ই-বুক বা pdf বই " সুচিপত্র ...বুকমার্ক মেনু 🔖 ও হাইপার লিংক মেনু 📝👆 যুক্ত ..
আমাদের সবার জন্য খুব খুব গুরুত্বপূর্ণ একটি বই ..বিসিএস, ব্যাংক, ইউনিভার্সিটি ভর্তি ও যে কোন প্রতিযোগিতা মূলক পরীক্ষার জন্য এর খুব ইম্পরট্যান্ট একটি বিষয় ...তাছাড়া বাংলাদেশের সাম্প্রতিক যে কোন ডাটা বা তথ্য এই বইতে পাবেন ...
তাই একজন নাগরিক হিসাবে এই তথ্য গুলো আপনার জানা প্রয়োজন ...।
বিসিএস ও ব্যাংক এর লিখিত পরীক্ষা ...+এছাড়া মাধ্যমিক ও উচ্চমাধ্যমিকের স্টুডেন্টদের জন্য অনেক কাজে আসবে ...
How to Build a Module in Odoo 17 Using the Scaffold Method
Odoo provides an option for creating a module by using a single line command. By using this command the user can make a whole structure of a module. It is very easy for a beginner to make a module. There is no need to make each file manually. This slide will show how to create a module using the scaffold method.
Hindi varnamala | hindi alphabet PPT.pdf
हिंदी वर्णमाला पीपीटी, hindi alphabet PPT presentation, hindi varnamala PPT, Hindi Varnamala pdf, हिंदी स्वर, हिंदी व्यंजन, sikhiye hindi varnmala, dr. mulla adam ali, hindi language and literature, hindi alphabet with drawing, hindi alphabet pdf, hindi varnamala for childrens, hindi language, hindi varnamala practice for kids, https://www.drmullaadamali.com
PCOS corelations and management through Ayurveda.
This presentation includes basic of PCOS their pathology and treatment and also Ayurveda correlation of PCOS and Ayurvedic line of treatment mentioned in classics.
BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...
BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...Nguyen Thanh Tu Collection
https://app.box.com/s/y977uz6bpd3af4qsebv7r9b7s21935vdMain Java[All of the Base Concepts}.docx
This is part 1 of my Java Learning Journey. This Contains Custom methods, classes, constructors, packages, multithreading , try- catch block, finally block and more.
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)Academy of Science of South Africa
A workshop hosted by the South African Journal of Science aimed at postgraduate students and early career researchers with little or no experience in writing and publishing journal articles.DRUGS AND ITS classification slide share
Any substance (other than food) that is used to prevent, diagnose, treat, or relieve symptoms of a
disease or abnormal condition
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS Template 2023-2024 by: Irene S. Rueco
How to Add Chatter in the odoo 17 ERP Module
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama UniversityAkanksha trivedi rama nursing college kanpur.
Natural birth techniques are various type such as/ water birth , alexender method, hypnosis, bradley method, lamaze method etcRecently uploaded (20)
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
How to Build a Module in Odoo 17 Using the Scaffold Method
How to Build a Module in Odoo 17 Using the Scaffold Method
Digital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental Design
BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...
BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama University